TY - JOUR
T1 - Metabolic predictors of response to immune checkpoint blockade therapy
AU - Shorer, Ofir
AU - Yizhak, Keren
N1 - © 2023 The Author(s).
PY - 2023/11/17
Y1 - 2023/11/17
N2 - Metabolism of immune cells in the tumor microenvironment (TME) plays a critical role in cancer patient response to immune checkpoint inhibitors (ICI). Yet, a metabolic characterization of immune cells in the TME of patients treated with ICI is lacking. To bridge this gap we performed a semi-supervised analysis of ∼1700 metabolic genes using single-cell RNA-seq data of > 1 million immune cells from ∼230 samples of cancer patients treated with ICI. When clustering cells based on their metabolic gene expression, we found that similar immunological cellular states are found in different metabolic states. Most importantly, we found metabolic states that are significantly associated with patient response. We then built a metabolic predictor based on a dozen gene signature, which significantly differentiates between responding and non-responding patients across different cancer types (AUC = 0.8–0.92). Taken together, our results demonstrate the power of metabolism in predicting patient response to ICI.
AB - Metabolism of immune cells in the tumor microenvironment (TME) plays a critical role in cancer patient response to immune checkpoint inhibitors (ICI). Yet, a metabolic characterization of immune cells in the TME of patients treated with ICI is lacking. To bridge this gap we performed a semi-supervised analysis of ∼1700 metabolic genes using single-cell RNA-seq data of > 1 million immune cells from ∼230 samples of cancer patients treated with ICI. When clustering cells based on their metabolic gene expression, we found that similar immunological cellular states are found in different metabolic states. Most importantly, we found metabolic states that are significantly associated with patient response. We then built a metabolic predictor based on a dozen gene signature, which significantly differentiates between responding and non-responding patients across different cancer types (AUC = 0.8–0.92). Taken together, our results demonstrate the power of metabolism in predicting patient response to ICI.
KW - Cancer
KW - Human metabolism
KW - Immunology
UR - http://www.scopus.com/inward/record.url?scp=85174829321&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2023.108188
DO - 10.1016/j.isci.2023.108188
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37965137
AN - SCOPUS:85174829321
VL - 26
SP - 108188
JO - iScience
JF - iScience
IS - 11
M1 - 108188
ER -